A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

Gynecological Malignancies Clinical Trial

Official title:
A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 for Injection in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

Status Recruiting

Clinical Trial Summary

This study is a single-arm, open, multicenter, non-randomized phase Ib/II clinical study evaluating the efficacy and safety of BL-M07D1 for injection in patients with HER2-expressing recurrent or metastatic gynecologic malignancies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06131450
Study type	Interventional
Source	Sichuan Baili Pharmaceutical Co., Ltd.
Contact	Hai Zhu, PHD
Phone	+8613980051002
Email	zhuhai@baili-pharm.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	February 29, 2024
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05914974` - Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies
Completed	`NCT00121030` - Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy	Phase 2
Completed	`NCT00770536` - AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR	Phase 1
Recruiting	`NCT06151028` - An Observational Study of Menopausal Symptom in Patients With Gynecological Malignancy After Oophorectomy
Recruiting	`NCT04905329` - A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations
Not yet recruiting	`NCT02718209` - The Development of an In-vitro System to Identify Gynecologic Cancer Cells During Surgical Procedures	N/A